Key result
HCM mutations E180G and D175N destabilize tropomyosin, increasing thin filament calcium sensitivity tied to disease severity.
Why the study?
To produce wild-type and mutant tropomyosin proteins (E180G and D175N) linked to familial hypertrophic cardiomyopathy and investigate their thermal stability differences.
HCM mutations E180G and D175N locally destabilize tropomyosin, which may lead to increased thin filament calcium sensitivity and correlate with the clinical severity of familial hypertrophic cardiomyopathy.
Should not yet influence HCM management; extends mechanistic insights into mutation-specific disease severity.
Background The expansion of the causative mutations to the rigid thin filament changed the description of hypertrophic cardiomyopathy (HCM) from an illness of the cardiac motor to a syndrome of the cardiac sarcomere and significantly extended the gasp of the potential molecular pathogenic mechanism. An interesting hypothesis concerning disease mechanism posted that the diverse medical prognoses in the familial type of HCM may possibly be related to mutations in self-regulating protein machinery of the sarcomere. The current studies conducted by some researchers elaborated on the various genetic alterations inside the genes encoding for the sarcomere cardiac proteins, alpha tropomyosin, troponin T, and myosin protein components. The regularity of gene alteration in the alpha tropomyosin protein (TPM1) is lesser, contributing to 5% of FHC. Currently, the D175N gene mutation has been recognized in various unrelated populations, signifying that this spot could be an abnormal gene “hot spot” for the disease. Purpose The aims and objectives of this project research is to produce a wild type of normal protein and mutant genetic proteins (E180G and D175N) which are clinically involved in familial hyper cardiomyopathy (FHCM). Bearing in mind that the main effect of mutations E180G and D175N are mainly related to the thermal stability of the protein; this research also investigated the differences between the thermal stability of wild type and mutated protein types using a Dye base fluorescent method of analysis. Methods (1)Preparation and Storage of Competent XL-1, BL2 and Escherichia Coli Cells applicable to transformation and transfection (2) Tropomyosin Preparation (3) DNA Purification (4) Column Chromatography analysis of tropomyosin (Wild Type Protein) (5) Preparation of mutated Protein (D175N and E180G) (Site Directed Mutagenesis) (6) Column Chromatography analysis of mutated Proteins (7) Measurement of the thermal Stability of Wild Type (Lysozyme) and mutated proteins (D175N and E180G) Using the Dye Base Fluorescent method (8) Media culture of XL1 cells and BL2 on agar media (9) DNA and protein gel electrophoresis (10) Resuspension of protein pellet with Potassium Phosphate. Results A wild type of normal protein and mutant genetic proteins (E180G and D175N) which are clinically involved in familial hyper cardiomyopathy (FHCM) were produced. The DNA and protein gel electrophoresis was conducted and the presence of the protein on the protein bands was noted, which indicates a high synthesis and purification process. The absorbance of tropomyosin normal protein using spectrophotometer measurements was performed and the molecular weight of the protein was found to be 32797 Da. At 280 nm wavelength, the absorbance of the protein was 0.129, and the protein concentration was found to be 11.64mg/ml. The absorbance of D175N protein using spectrophotometer measurements was conducted and the molecular weight of the protein was found to be 32797 Da. At 280 nm wavelength, the absorbance of the protein was 0.032, and the protein concentration was found to be 5.25mg/ml. The absorbance of E180G protein using spectrophotometer measurements was conducted and the molecular weight of the protein was found to be 32797 Da. At 280 nm wavelength, the absorbance of the protein was 0.031, and the protein concentration was found to be 5.43mg/ml. Thermal denaturation studies of normal tropomyosin and mutant tropomyosin (E180G and D175N) show a cooperative interaction between folding of the N-domain and C-regions of tropomyosin. HCM mutations E180G and D175N prominently destabilized the tropomyosin N-domain, which indirectly affected cooperative interactions between N- and C-terminal regions of tropomyosin. Conclusion Recombinant human tropomyosin’s were produced which serves as a model protein to study the interactions that govern the stability of the thin filament. Two mutations (E180G and D175N) described as causing cardiomyopathy were introduced in the cDNA encoding the human skeletal muscle tropomyosin. Thermal denaturation studies of control and mutant tropomyosin (E180G and D175N) show a cooperative interaction between folding of the N-domain and C-regions of tropomyosin. HCM mutations E180G and D175N prominently destabilized the tropomyosin N-domain, which indirectly affected cooperative interactions between N- and C-terminal regions of tropomyosin. The experimental result on this current study suggested that HCM mutations locally destabilize tropomyosin, leading to an increased thin filament Calcium sensitivity, and the degree of disruption of the tropomyosin interaction by the FHC mutations may be directly correlated with the severity of the disease. For future prospect, future biochemical analysis of several other FHC mutations will be needed to establish a definite correlation between the enzymatic impairment between different mutants and their clinical phenotype of heart disease.
No takes yet. Share an insight, caveat, or question.
Ugochukwu Obinna Maluze (2026) studied this question. Hypertrophic cardiomyopathy mutations E180G and D175N destabilize the tropomyosin N-domain, increasing thin filament calcium sensitivity that may correlate with disease severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: